sebetralstat
Trade name: Ekterly
Small moleculeapprovedOrphan Drug FDA
Approved
Jul 3, 2025
Clinical trial activity
8 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Jan 4, 2018 (NCT04349800)
Timeline
2010s
- Jan 1, 2018
KalVista Pharmaceuticals, Ltd. — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2019
KalVista Pharmaceuticals, Ltd. — Earliest Phase 2 Sponsor(trial)
2020s
- Sep 7, 2021
Orphan Drug Designation
- Jan 1, 2022
KalVista Pharmaceuticals, Ltd. — Earliest Phase 3 Sponsor(trial)
- Jul 3, 2025
Earliest FDA Approval
- Jul 3, 2025
KalVista Pharmaceuticals, Ltd. — Marketing Organization
Indications
Approved for
Mechanism of action
- Kallikrein 1INHIBITOR
KLK1 inhibitor
Approval history
- approvedJul 3, 2025
Chemistry & pharmacology
Loading structure…
SMILES
COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F- Mol. weight
- 491.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095248 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06467084 | Phase 3 | Jun 24, 2024 | KalVista Pharmaceuticals, Ltd. |
| NCT05511922 | Phase 3 | Oct 24, 2022 | KalVista Pharmaceuticals, Ltd. |
| NCT05505916 | Phase 3 | Oct 24, 2022 | KalVista Pharmaceuticals, Ltd. |
| NCT05259917 | Phase 3 | Feb 23, 2022 | KalVista Pharmaceuticals, Ltd. |
| NCT04208412 | Phase 2 | Jul 2, 2019 | KalVista Pharmaceuticals, Ltd. |
| NCT04349800 | Phase 1 | Jan 4, 2018 | KalVista Pharmaceuticals, Ltd. |
| NCT06628713 | N/A | — | KalVista Pharmaceuticals, Ltd. |
| NCT07216378 | N/A | — | KalVista Pharmaceuticals, Ltd. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Ltd. | For profit | 8 | 8 | 4 | 2018 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| KalVista Pharmaceuticals, Ltd. | For profit | MKTG | Jul 3, 2025 |